Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-06
1998-07-21
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514626, A61K 3142, A61K 31165
Patent
active
057835926
ABSTRACT:
The present invention features pharmaceutical formulations containing a lipophilic compound that is solubilized in a solution containing ethanol and a surfactant. The solubilized compound can then be further dissolved in a pharmaceutically acceptable aqueous solution, such as WFI (water for injection), D5W (5% dextrose in water) and D5W 1/2 N saline, to form a pharmaceutical formulation suitable for patient administration. The formulation is preferably used for parenteral administration.
REFERENCES:
patent: 4087535 (1978-05-01), Heubach et al.
patent: 4284786 (1981-08-01), Kammerer et al.
patent: 4351841 (1982-09-01), Kammerer et al.
patent: 4992271 (1991-02-01), Fernandez et al.
patent: 5268382 (1993-12-01), Bartlett et al.
patent: 5314685 (1994-05-01), Tyle et al.
patent: 5403858 (1995-04-01), Bastard et al.
patent: 5573775 (1996-11-01), Robertson et al.
Andrews et al., (American Veterinary Medicine Association Panel on Euthanasia), "1993 Report of the AVMA Panel on Authanasia", J. American Veterinary Medicine Association 202(2):229-249 (1993).
Bartlett et al., "Effects of leflunomide on immune responses and models of inflammation," Springer Semin. Immunopathol. 14:381-394 (1993).
Bartlett et al., "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection," Agents and Actions 32:10-21 (1991).
Bartlett et al., "Leflunomide: A novel immunomodulating drug" in Nonsteroidal Anti-Inflammatory Drugs 2nd ed. pp. 349-366, Lewis and Furstk eds., Dekker, NY, NY (1991).
Bristol Labortories Oncology Products, "VePesid (Etoposide) For Injection and Capsules," Dec. 1992.
Cecil Textbook of Medicine, eds. Wyngaarden, Smith, Bennett, W.B. Saunders (1992) p. 2220.
Cherwinski et al., "The Immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism," J. Pharmacology and Exp. Therap. 272:460-468 (1995).
Chong et al., "Leflunomide, a Novel Immunomodulatory Agent: In Vitro Analyses of the Mechanism of Immunosupression," Transplant. Proc. 25:747-749 (1993).
Chong et al., "Leflunomide, a Novel Immuosupressive Agent," Transplantation 55:1361-1366 (1993).
Glant et al., "Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide," Immunopharmacology 23:105-116 (1992).
Hambleton and Mahon, "Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis," Agents and Actions 29:328-332 (1990).
Ju et al., "Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture," Acta Pharmacological Sinica 15:223-226 (1994).
Ju et al., "Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritomeal macrophages," Acta Pharmacological Sinica 92:90-94 (1994).
Kuechle et al., "Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immodulating Agent," Transplant Proc. 23:1083-1806 (1991).
Mattar et al., "Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide," FEBS Letters 2:161-164 (1993).
McChesney et al., "An Evaluation of Leflunomide in the Canine Renal Transplantation Model," Transplantation 57:1717-1722 (1994).
Nichterlein et al., "Leflunomide (HWA 486) Prolongs Course of Murine Listeriosis," Immunol. Infect. Dis. 4:18-22 (1994.
Ogawa et al., "Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats," Agents Actions 31:321-328 (1990).
Ogawa et al., "Therapeutic Effects of Leflunomide, a New Antirheumatic Drug, on Glomerulonephritis Induced by the Antibasement Membrane Antibody in Rats," Clin. Immunol. Immunopath. 61:103-118 (1991).
Ross, "The pathogenesis of atherosclerosis: a perspective for the 1990s," Nature 362:801-809 (1993).
Satou Fumihiro, "Injection Containing Etoposide," Application No. JP60239415 published Nov. 28, 1995, Application No. JP84009559 dated May 15, 1984, Patent Abstract of Japan vol. 105, No. 112 (C-342).
Schorlemmer et al., "Prolongation of Allogeneic Transplanted Skin Grafts and Induction of Tolerance by Leflunomide, a New Immunosuppressive Isoxazol Derivative," Transplant. Proc. 25:763-767 (1993).
Thoenes et al., "Leflunomide (HWA 486) Inhibits Experimental Autoimmune Tubulointersitial Nephritis in Rats," Int. J. Immunopharmacol. 11:921-929 (1989).
Ulrichs et al., "Suppression of Natural Xenophile Antibodies With the Novel Immunomodulating Drug Leflunomide,," Transplant Proc. 24;718-719 (1992).
Weithmann et al., "Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation," Agents Actions 41:164-170 (1994).
Williams et al., "Immunosupressive Effects of Leflunomide in a Cardiac Allograft Model," Transplantation Proc. 25:745-746 (1993).
Williams et al., "Leflunomide in Experimental Transplantation," Transplantation 57:1223-1231 (1994).
Xiao et al., "Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts," Transplantation 58:828-834 (1994).
Xiao et al., "Effect of Leflunomide in Control of Acute Rejection in Hamster-to-Rat Cardiac Xenografts," Transplantation Proceedings 26:1263-1265 1994).
Zielinski et al., "Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers," Agents Actions 38:Special Conference Issue) C80-C82 (1993).
Schwartz Donna Pruess
Shawver Laura Kay
Baylor College of Medicine
Spivack Phyllis G.
LandOfFree
Formulations for lipophilic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations for lipophilic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for lipophilic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1647373